Abstract: The present invention refers to NPY Y1 receptor-targeting peptide moieties, and their use for the target-specific treatment of cancers and other diseases.

Abstract: The present invention relates to a combination of natural substances comprising at least one glycyrrhetinic acid and at least one guggulsterone, and to the use thereof for cosmetic applications. The present invention relates especially to vesicles (especially for topical application) comprising at least one glycyrrhetinic acid and at least one guggulsterone. The vesicles are preferably added to a cream, a lotion or a gel, the resulting cream, lotion or gel being used for the cosmetic and/or dermatological treatment of the skin and/or for the prophylaxis of the appearance of cellulite and/or ageing skin and/or for the treatment of changes in subcutaneous fatty or connective tissue, for example lipomas and other non-specific subcutaneous fat deposits, or for the regression or reduction of fat pads which are not caused by disease, such as, for example, fat pads in the face and neck region, for example lachrymal sacs, etc.

Abstract: The present invention relates to a method for diagnosing a G-protein coupled receptor-related disease in one or more target cells, comprising: selecting a G-protein coupled receptor, the receptor being characterized in that it is: (i) differentially expressed in the target cells as compared to healthy control cells, wherein the expression level in the target cells is at least 10 times the expression level in the control cells; (ii) activated by a peptide ligand or a protein ligand; and (iii) upon activation by binding of a ligand efficiently internalized into the one or more target cells together the peptide ligand or protein ligand, wherein an internalization of at least 30% of the G-protein coupled receptor initially present in the cell membrane of the one or more target cells within less than 30 minutes after activation is indicative for the diagnosis of a G-protein coupled receptor-related disease.

Abstract: The present invention refers to neuropeptide Y receptor 1 (NPY-1) binding ligands linked to cytotoxic molecules and their use for the treatment of cancer and other diseases.